Vaccines need to be studied to assess effectiveness against new variants of the coronavirus

The American pharmaceutical company Novavax has released results about the efficacy of its vaccine - claiming it's 95 per cent effective against the original version of Covid-19.

But it's less effective against the fast-spreading variant of the virus that's now become dominant in South Africa. Hear the interview